

UnitedHealthcare Community Plan of Mississippi Medical Policy Update Bulletin Quick View: July 2024



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. For a comprehensive summary of the latest updates, refer to the Medical Policy Update Bulletin: July 2024.

Take Note

Update: Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins

The Medical Policy titled *Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins* will not be revised on Aug. 1, 2024, as previously announced. Details on upcoming changes to this policy will be provided in a future edition of the Medical Policy Update Bulletin.

Quarterly CPT® and HCPCS Code Updates

Effective **Jul. 1, 2024**, all applicable Medical Policies and Medical Benefit Drug Policies have been updated to reflect the quarterly Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- American Medical Association: Current Procedural Terminology: CPT®
- Centers for Medicare & Medicaid Services: Healthcare Common Procedure Coding System (HCPCS) Quarterly Update

Refer to the Medical Policy Update Bulletin: July 2024 for a list of impacted policies and corresponding details.

Medical Policy Updates

| Policy Title | Status | Effective Date |
|---|---------|----------------|
| Ambulance Services (for Mississippi Only) | Updated | Sep. 1, 2024 |
| Fecal Calprotectin Testing | Retired | Jul. 1, 2024 |
| Gastrointestinal Motility Disorders, Diagnosis and Treatment (for Mississippi Only) | Revised | Sep. 1, 2024 |
| Gynecomastia Surgery (for Mississippi Only) | Revised | Sep. 1, 2024 |
| Manipulative Therapy (for Mississippi Only) | Revised | Sep. 1, 2024 |
| Panniculectomy and Body Contouring Procedures (for Mississippi Only) | Revised | Sep. 1, 2024 |
| Surgery of the Foot | Revised | Sep. 1, 2024 |
| Surgery of the Hand or Wrist | Updated | Sep. 1, 2024 |

Medical Benefit Drug Policy Updates

| Policy Title | Status | Effective Date |
|---|---------|-----------------------|
| 17-Alpha-Hydroxyprogesterone Caproate (Makena® and 17P) | Retired | Jul. 1, 2024 |
| Antiemetics for Oncology | Updated | Jul. 1, 2024 |
| Brineura® (Cerliponase Alfa) | Revised | Aug. 1, 2024 |
| Gene Therapies for Hemophilia B | Revised | Aug. 1, 2024 |
| Immune Globulin (IVIG and SCIG) | Revised | Aug. 1, 2024 |
| Maximum Dosage and Frequency | Revised | Aug. 1, 2024 |

| Policy Title | Status | Effective Date |
|--|---------|----------------|
| Medical Therapies for Enzyme Deficiencies | Revised | Aug. 1, 2024 |
| Oncology Medication Clinical Coverage | Revised | Aug. 1, 2024 |
| Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) | Revised | Aug. 1, 2024 |
| Rituximab (Riabni [®] , Rituxan [®] , Ruxience [®] , & Truxima [®]) | Revised | Aug. 1, 2024 |
| RNA-Targeted Therapies (Amvuttra® and Onpattro®) | Revised | Aug. 1, 2024 |
| Xolair® (Omalizumab) | Revised | Aug. 1, 2024 |

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Community Plan of Mississippi Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of Medical Policies and Medical Benefit Drug Policies for UnitedHealthcare Community Plan of Mississippi is available at **UHCprovider.com/MS** > Medicaid (Community Plan) > Current Policies and Clinical Guidelines > Medical & Drug Policies.